GeneDx Holdings Corp (WGS) concluded trading on Wednesday at a closing price of $66.85, with 7.61 million shares of worth about $509.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 13.65% during that period and on April 30, 2025 the price saw a loss of about -42.85%. Currently the company’s common shares owned by public are about 28.02M shares, out of which, 24.94M shares are available for trading.
Stock saw a price change of -36.75% in past 5 days and over the past one month there was a price change of -24.52%. Year-to-date (YTD), WGS shares are showing a performance of -13.02% which increased to 503.34% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.90 but also hit the highest price of $117.75 during that period. The average intraday trading volume for GeneDx Holdings Corp shares is 1.05 million. The stock is currently trading -29.99% below its 20-day simple moving average (SMA20), while that difference is down -30.46% for SMA50 and it goes to -1.42% lower than SMA200.
GeneDx Holdings Corp (NASDAQ: WGS) currently have 28.02M outstanding shares and institutions hold larger chunk of about 84.74% of that.
The stock has a current market capitalization of $1.91B and its 3Y-monthly beta is at 1.95. It has posted earnings per share of -$1.99 in the same period. It has Quick Ratio of 3.42 while making debt-to-equity ratio of 0.48. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for WGS, volatility over the week remained 10.35% while standing at 9.77% over the month.
Stock’s fiscal year EPS is expected to rise by 277.81% while it is estimated to increase by 100.52% in next year. EPS is likely to grow at an annualized rate of 121.82% for next 5-years, compared to annual growth of 96.65% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on August 28, 2024 offering an Equal weight rating for the stock and assigned a target price of $34 to it. Coverage by Craig Hallum stated GeneDx Holdings Corp (WGS) stock as a Buy in their note to investors on July 10, 2024, suggesting a price target of $43 for the stock.
